Berlin, Germany

Stuart Ince

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 8.1

ph-index = 3

Forward Citations = 36(Granted Patents)


Company Filing History:


Years Active: 2007-2017

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Stuart Ince

Introduction

Stuart Ince is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of kinase inhibitors. With a total of 15 patents to his name, Ince's work has had a substantial impact on cancer treatment methodologies.

Latest Patents

Among his latest patents, Ince has developed "Imidazopyridazines as Akt kinase inhibitors." This invention relates to a method for treating cancers sensitive to Pi3K/Akt pathway inhibition by administering a therapeutically effective amount of a compound of formula (I). Another notable patent is for "Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors." This invention involves substituted aminoquinoxaline compounds of general formula (I), detailing methods of preparation, pharmaceutical compositions, and their use in treating or preventing diseases.

Career Highlights

Ince has worked with notable companies such as Bayer Schering Pharma AG and Bayer Intellectual Property GmbH. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovation and patent development.

Collaborations

Throughout his career, Ince has collaborated with esteemed colleagues, including Ulf Bömer and Karl-Heinz Thierauch. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Stuart Ince's innovative work in the field of pharmaceuticals, particularly in kinase inhibitors, showcases his dedication to advancing cancer treatment. His numerous patents and collaborations highlight his significant contributions to medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…